Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Overall survival, according to treatment group

Published byEmerald Maxwell Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3 Overall survival, according to treatment group"— Presentation transcript:

1 Figure 3 Overall survival, according to treatment group
Figure 3 | Overall survival, according to treatment group. Results from the Radiation Therapy Oncology Group (RTOG) 9802 trial7. All hazard ratios in the analyses of overall survival are for death, and all P values are two-sided. Tick marks indicate censored data. There were too few events among patients without the IDH1 Arg132His mutation to assess the association with treatment. PCV, procarbazine, lomustine and vincristine; RT, radiation therapy. From The New England Journal of Medicine, Buckner, J. C. et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, 374, 1344–1355. Copyright © (2016) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. From The New England Journal of Medicine, Buckner, J. C. et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, 374, 1344–1355. Copyright © (2016) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Buckner, J. et al. (2017) Management of diffuse low-grade gliomas in adults — use of molecular diagnostics Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Figure 3 Overall survival, according to treatment group"

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Outcome of Salvage Total Laryngectomy Following Organ.

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Outcome of Salvage Total Laryngectomy Following Organ.
Date of download: 11/13/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stereotactic Radiosurgery Plus Whole-Brain Radiation.

Date of download: 11/13/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stereotactic Radiosurgery Plus Whole-Brain Radiation.
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.
Figure 4 Progression-free survival, according to treatment group

Figure 4 Progression-free survival, according to treatment group
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Figure 1 Histopathology of low-grade glioma

Figure 1 Histopathology of low-grade glioma
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 3 Molecular subgroups of glioblastoma,

Figure 3 Molecular subgroups of glioblastoma,
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.
Understanding EMPA-REG OUTCOME

Understanding EMPA-REG OUTCOME
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Proportion of patients for whom NEDA

Figure 3 Proportion of patients for whom NEDA
Figure 5 Number of AHSCT procedures for

Figure 5 Number of AHSCT procedures for
Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 1 Diagnostic tiers of Parkinson disease as single disease
Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 2 The association between CD8+ T‑cell density of the tumour

Similar presentations

Ads by Google